Introduction
In industrialized settings, antiretroviral therapy (ART), with at least three potent antiretroviral (ARV) drugs is recommended to prevent mother-to-child transmission (PMTCT) of HIV, even in women with no indication for themselves, and ART should be initiated, in this case, as soon as possible after the first trimester and stopped soon after delivery . However, in the United States, short-course regimens of one or [1] [2] [3] two ARVs are still an option for women with plasma viral load <1000 copies/mL, or for those who are screened for HIV late in pregnancy or during labour . In resource-limited settings, ART is recommended only in pregnant women with indication of treatment for themselves, [1] while those who do not meet clinical and immunologic eligibility criteria for ART accordingly to the World Health Organization (WHO) guideline should receive short-course ARV regimens . With the large international mobilization against HIV/AIDS and the great [4] improvement of ARV drug access within the last five years in resource-limited countries, more HIV-infected people have access to ART, including pregnant women . In this context, should indications of ART in pregnant women in resource-limited settings be enlarged? We [5] review here the recent reported evidence on the implementation and effectiveness of the current recommendations for PMTCT in resource-limited countries and on the impact of such regimens on subsequent use of ARVs for treatment or prophylaxis, as well as the potential new indication of ART in pregnant women, the breastfeeding period.
Coverage and effectiveness of PMTCT programmes
The WHO currently recommends the administration of zidovudine (ZDV) initiated as soon as possible from the 28 week of gestation, th together with single-dose nevirapine (sdNVP) during labor and seven days of ZDV lamivudine (3TC) postpartum . The neonate should + [6] receive sdNVP and one week of ZDV syrup. Alternatives are possible, according to the local programme implementation capacities and the timing of the maternal screening for HIV infection, the minimum ARV regimen recommended being the administration of sdNVP to the mother and the neonate. However, in many settings reporting their experience in implementing PMTCT programmes, this minimum regimen is the one mainly used, despite the fact that antenatal short-course ZDV has been recommended since 2000 and proved to be safe , .
Altogether, the worldwide coverage of PMTCT interventions remains low, with about 10 of HIV infected pregnant women receiving any % ARV prophylaxis , . In addition, difficulties in evaluating PMTCT programmes were recently highlighted, including the inadequacy of [5 the probabilities of pediatric HIV infection or death were similar, about 11 12 in the two groups. In the ART group, 7.5 of women can be obtained as reported in well organized programmes with adequate monitoring. However, difficulties to implement such link as well as more complex interventions (adding antepartum ZDV, for instance) remain with the negative consequences on the overall effectiveness and coverage of the programmes. These are the primary reasons while sdNVP remains the most commonly adopted PMTCT regimen, despite its disadvantages including viral resistance.
Nevirapine viral resistance
The concern of Non Nucleosid Reverse Transcriptase Inhibitor (NNRTI) viral resistance induced by sdNVP is of high importance today as it has been for the past three to five years. A recent meta-analysis has estimated the prevalence of NVP resistant mutants at 4 8 weeks [17] previous sdNVP on virologic response to NNRTI-containing ART regimen, in women, particularly if it was initiated less than six months after delivery; the conclusion was quite comparable in children . In this study, conducted in Botswana, where women were randomized to
receive either sdNVP or placebo for PMTCT, the authors observed that, in women initiating ART within six months after delivery, virologic failure rate at six months was higher in women previously exposed than among those not exposed (41.7 vs. 0 , respectively). This negative % % impact was not observed in women initiating therapy more than six months after delivery, and was not observed either for immunologic
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response irrespective of the sub-group. Another study, conducted in Zambia, from routine data collected in public ART facilities did not show any difference in terms of immunologic and clinical response to NNRTI-containing treatment at 12 months whatever sdNVP previous [19] exposure, recent or remote. In C te d Ivoire, no negative impact of previous sdNVP was observed on virologic or immunologic response at 12
months of women starting NNRTI-based regimen, but the median delay between delivery and ART initiation was long: 28 months .
[20]
However, it is worth noting that 3TC viral resistance at 4 weeks postpartum was associated with virologic failure at 12 months, despite a median delay of 15 months between delivery and ART initiation, confirming that this drug should not be recommended antenatally as a part of short-course PMTCT regimen (in this context: short-course ZDV/3TC sdNVP). Recent findings from South Africa and C te d Ivoire also
demonstrated that previous exposure to sdNVP did not lower the efficacy of this regimen in a subsequent pregnancy .
[21]
A study conducted in South Africa confirmed the high prevalence of NNRTI resistance mutations in children exposed to sdNVP, with 45%
of HIV-infected infants harbouring resistant virus by 12 weeks of age . The authors noticed that the 18-month mortality rate they found
(454 deaths per 1000 child-years) was higher than those reported for HIV-infected children in sub-Saharan Africa. This findings could be related to the negative impact of sdNVP exposure observed in the Botswana study for both immunological and virologic response of NNRTI-based ART in infants at six months, possibly as a result of selection of resistant virus . Furthermore, Martinson et al. observed that [18] infant detectable viral resistance was associated with higher maternal plasma HIV viral load during pregnancy suggesting that ART provided to pregnant women with advanced HIV disease may reduce selection of resistance in infants, when infected . In another study conducted in [22] South Africa, where only sdNVP was available for PMTCT, most children (69 ) who had been infected despite sdNVP administration were % infected in utero from mothers with lower CD4 and higher plasma viral load than mothers of uninfected children . It has also been
observed that transmission after six months of life accounted for >85 of late postnatal infant HIV infections in this breastfeeding population % and was also associated with higher baseline maternal viral load . The authors speculated that this pattern could have been influenced by
the disappearance of NVP resistance virus six months after delivery and the emergence of wild-type virus, with probable better fitness to replicate in the breastmilk compartment.
Altogether, these studies demonstrate that advanced maternal ARV disease during pregnancy have negative consequences, not only on the MTCT rate, but also on disease progression and development of viral resistance in children infected despite sdNVP, clearly an inappropriate intervention for this population.
To summarize, these recent data confirm the safety of sdNVP use in the context of WHO recommendations but highlight the urgent need to implement PMTCT programmes allowing for effective ART in women who have the indication and for minimizing the overall risk of resistance by offering postpartum short-course ZDV 3TC .
Antiretroviral regimens for PMTCT via breastfeeding
There are currently two approaches for the use of ARV regimens to prevent MTCT during breastfeeding: providing ART to pregnant women and prolonged during lactation or providing post-exposure prophylaxis to the infant.
Some experiences of the first approach were reported during the 2007 IAS conference. In the AMATA study (Rwanda), all women received NNRTI-based ART starting after the second trimester of pregnancy and were given the choice between formula feeding (FF) and breastfeeding (BF) with weaning at 6 months . About 57 of the women opted for FF. At 7 months of age, 1.6 of children were [25] % % diagnosed with HIV infection, including six infections at birth and only one through breastfeeding. No significant difference in morbidity or in mortality was observed. In the MITRA PLUS study (Tanzania) , an open-label non-randomized prospective cohort, women were treated with ZDV/3TC/NVP during late pregnancy and BF , from 34 weeks of gestation or earlier if the woman had indication. The infants received [26] ZDV/3TC for one week after birth. Mothers were counselled on exclusive BF and encouraged to stop at six months. The cumulative proportion of HIV-1 infected infants was 5.0 (95 CI 3.2 7.0 ) at 6 months. Thus, this strategy appeared in line with the findings from the DREAM % % -% cohort (Mozambique): HIV RNA levels in breastmilk were significantly lower in women on ART than in untreated women (median of 2.3 vs.
3.4 log at delivery and 1.9 vs. 3.6 log at day 7) . [27] Thus, these two cohort studies showed a low HIV-1 transmission rate in breastfeeding populations receiving ART, with the advantage that mothers eligible for ART benefited from treatment for their own health as well. However, using ART as a prophylactic regimen in women who are not eligible for a treatment for themselves raises the issue of its subsequent cessation. A Thailand study proposed to assess the impact [28] of stopping ART postpartum, comparing two historical cohorts of women not eligible for ART for themselves and followed-up for 15 months after delivery. The first one received ZDV from 32 weeks and sdNVP and the second one ZDV/3TC/NVP from 28 weeks 1 week ZDV/3TC.
+
They did not observe any difference in terms of death/clinical progression between the two groups.
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However, women with a CD4 count<350 cells/mm3 were at higher risk for ART need shortly after delivery suggesting that ART should not be stopped in this population.
Providing post-exposure prophylaxis to the infant, the second approach of use of ARV regimens to prevent MTCT during breastfeeding was reported in a recent publication from the Mashi Study . In this study, mothers received short-course ZDV antenatally and during [29**] labor. Mothers and infants were randomized to receive sdNVP or placebo. Infants were randomized to 6 months of BF and ZDV or formula feeding and ZDV for one month. The 7-month HIV infection rates were 9.0 in the first group and 5.6 in the second (p 0.04), but the % % = cumulative mortality was higher in the second group. Finally both strategies had comparable HIV-free survival at 18 months.
Conclusion
The use of fully suppressive ART initiated during pregnancy and the breasfeeding period, even in women with no indication of treatment, is a potentially highly effective PMTCT strategy and this may constitute a very relevant alternative when formula feeding is not judged to be safe or well accepted. However, potential risks for women s health of interrupting ART after delivery and for infants health of in utero ' ' continuous ART exposure are not fully ascertained. The increasing but still limited access to ARV may limit the implementation of such strategy and the risk of toxicity of NVP use in women with higher CD4 counts may require alternative drugs which are not widely available and closer monitoring. Antenatal care facilities should thus be strengthened to provide at least the preferred WHO recommended short-course PMTCT regimen for women with no treatment indication and effective referral to ART programmes for those women at high risk of HIV disease and mother-to-child transmission. It is thus likely that short-course have still a role to play in resource-limited settings for PMTCT, especially if the risk of NVP-induced resistance is controlled. Notwithstanding their role to be confirmed as a neonatal prophylaxis during breastfeeding.
